Research Projects

Understanding the genetics of Alzheimer's disease (AD) is one of the best ways of improving our knowledge of the disease's underlying pathophysiological processes. Indeed, genetic factors account for up to 70% of the attributable risk in common forms of AD. The advent of genomic approaches has led to the characterization of 26 genetic determinants...

FluiDx-AD aims to transform Alzheimer’s disease (AD) diagnosis and prepare the EU healthcare systems for the emergence of new AD therapies, with a 1st-in-class trio of In Vitro Diagnostics tests.FluiDx-AD tests detect a unique and proprietary suite of biomarkers in simple bodily fluids (saliva, plasma/blood), towards widespread, patient-empowering...

The DEM-CHILD project focusses on the main cause for childhood dementia in Europe, the neuronal ceroid lipofuscinoses (NCLs). The NCLs are neurodegenerative diseases characterized by dementia, blindness, epilepsy and physical decline leading to an early death of the patients. Since no cure is currently available, these disorders represent a serious...

Frontotemporal dementia (FTD) has a debilitating effect on patients and their caregivers and leads to substantial economic costs. 15-30% of patients have familial FTD caused by known pathogenetic mutations. For the other 70-85% of patients, termed sporadic FTD, diagnosis is slow (~3.6 years) with frequent misdiagnosis due to clinical, genetic and...

The JA will be contribute to public health programmes in Europe and develop Alzheimers disease (AD) and dementia prevention and care models in different European countries. The aim is to contribute to improvements in health by supporting and facilitating quality and efficiency of public health and healthcare policies and interventions. Synergy and...

Dementia is caused by a range of illnesses and disorders that damage the brain either directly or indirectly. With the rise of the ageing population in the EU, dementia is becoming a serious problem. Digital health interventions have the potential to improve the accessibility and effectiveness of palliative care. Palliative care is an area where...

Alzheimer's disease (AD) is the most common age-related neurodegerative disorder, and one of the most devastating diagnoses that patients and their families can receive. Currently ~10 % of over 65 year old have AD, and the direct and indirect cost of its care is estimated to be >100 billion $ in the US alone and in the UK ~ €22M, and therefore...

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Lipids are essential components of cell membranes. Every organelle membrane is constituted of a unique composition of different lipid species. This distinctive lipid distribution along organelle membranes is important to maintain the identity and functions of the different organelles. In this research project, I aim to understand how the lipid...

CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and determinants in Europe, and their socio-economic implications. 15 cohorts participate, covering populations from 18 EU Member States, 4 associate countries, and 3 additional countries. The combination of these...

Alzheimer’s disease (AD) is the leading cause of dementia, affecting over 50 million people worldwide. Characterized by memory loss, cognitive decline, and the formation of amyloid-β plaques and neurofibrillary tangles, AD presents a significant global health burden. Current AD models, particularly in mice, fail to accurately represent the sporadic...

Prevention of Alzheimer’s disease (AD) and dementia is a global public health priority. EURO-FINGERS builds upon the successful experiences of two multimodal prevention trials: the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) and the JPND-funded MIND-AD. The FINGER intervention trial showed that a...